Expert Interview
Discussing the recent FDA Approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis as a result of the data from the pivotal Phase 3 MycarinG study.
Ticker(s): UCBJYInstitution: North Texas Institute of Neurology, Headache
- Neurologist at North Texas Institute of Neurology & Headache.
- Manages 500 patients with myasthenia gravis
- Special interest in patients with neuromuscular diseases (i.e., peripheral neuropathy, myopathy, myasthenia gravis, etc.) and headaches
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
